ArticleIndian journal of pharmacology
A retrospective study of use of polyvalent anti-snake venom and risk factors for mortality from snake bite in a tertiary care setting.
Article in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Mortality due to snakebite and other venomous animals in the Indian state of Bihar: Findings from a representative mortality study.PloS one · 2018Trial
- Presentation, treatment profiles, and outcome of snake bite patients presented in emergency department at a tertiary hospital in Eastern Nepal.Journal of family medicine and primary care · 2024Article
- Clinical, laboratory profile and outcomes in children with snakebite from Eastern India.Journal of family medicine and primary care · 2023Article
- Multilevel Comparison of IndianToxins · 2023Article
- Augmented rescue of macroglobulins by supplementation of anti-snake venom with methanolic extract of3 Biotech · 2022Article
- Serious Adverse Reactions to Anti-snake Venom in Children with Snake Envenomation: An Underappreciated Contributor to Snakebite Mortality?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Ambispective study of clinical picture, management practices and outcome of snake bite patients at tertiary care centre in Northern India.Journal of family medicine and primary care · 2021Article
- Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study.eLife · 2020Article
- Comparative therapeutic index, lethal time and safety margin of various toxicants and snake antivenoms using newly derived and old formulas.BMC research notes · 2020Article
- The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites.Toxins · 2019Review
- Molecular docking and dynamic studies of crepiside E beta glucopyranoside as an inhibitor of snake venom PLA2.Journal of molecular modeling · 2019Article
- Mass awareness regarding snake bite induced early morning neuroparalysis can prevent many deaths in North India.International journal of critical illness and injury scienceArticle
- The North-South divide in snake bite envenomation in India.Journal of emergencies, trauma, and shockReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEnvenomation with poisonous snakes is associated with considerable morbidity and mortality. The present study was undertaken with the objectives of assessing anti-snake venom (ASV) use, early adverse reactions to ASV, premedication and clinical outcomes in snake bite patients. Association of various risk factors (age, gender, dose of ASV, time gap between snake bite and ASV administration, use of mechanical ventilation and type of snake bite) with mortality was also assessed. SETTINGS AND
designThis retrospective study was conducted at two Tertiary Care Teaching Hospitals. SUBJECTS AND
methodsThe medical records of 176 patients of snake bite with documented use of ASV were retrospectively analyzed to retrieve relevant data. STATISTICAL ANALYSIS: Descriptive statistics was used to express results about ASV use, early adverse reactions to ASV, premedication and clinical outcomes. Univariate and multivariate analysis was performed to find out significant risk factors associated with mortality.
resultsThe main indication for ASV was vasculotoxic snake bite (75%) followed by neurotoxic snake bite (16%). Mean dose of ASV was 18.63 ± 14.52 vials. Prophylactic premedication with corticosteroids alone or in combination with antihistaminic was used in more than 70% patients. Early adverse reactions to ASV were seen in 4% patients. Neurotoxic snake bite was a significant risk factor associated with mortality in multivariate analysis.
conclusionsNeurotoxic snake bite is an independent predictor of mortality in snake bite patients. Currently used polyvalent ASV may be less effective in treating neurotoxic snake bite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.